Summary:
- The article discusses an experimental drug called RK-33 that has shown promise in treating breast cancer that has metastasized to the bone.
- RK-33 works by inhibiting the activity of a protein called DDX3, which is involved in the growth and spread of cancer cells.
- In preclinical studies, RK-33 was found to reduce the size and number of bone metastases in animal models of breast cancer, suggesting it could be a potential new treatment option for this challenging form of the disease.